The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company delayed the results of COVID-19 vaccine trials to influence the 2020 election.

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the ...

Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work. The aim is to help “grasp ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

Pfizer Inc. has initiated a new clinical study titled A Phase 1, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and ...

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2 ...

The Pharmaceutical Suppositories Market presents strong growth opportunities, especially in regions with aging populations and rising chronic illnesses. Market drivers such as increasing pediatric ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Pfizer's Depo-Provera shot has been linked to brain tumors — and hundreds of women are suing the pharmaceutical giant over it.

Braftovi, acquired in Pfizer’s $10.6 billion buyout of Array BioPharma in 2019, has been steadily growing, winning approvals to treat patients with skin, lung and colorectal cancer whose tumors ...

Pfizer is in-licensing a bispecific antibody drug for cancer that China-based 3SBio designed to block the proteins PD-1 and VEGF. The deal puts the pharmaceutical giant in a growing group of ...